INTRODUCTION AND OBJECTIVES: C-reactive protein (CRP) is a systemic inflammatory marker which has been associated with overall survival (OS) in Renal Cell Carcinoma (RCC) patients in Asia. Data supporting utility of CRP as a predictive marker in non-Asian populations are sparse and controversial. We analyzed utility of pretreatment CRP as a predictor of survival and oncological outcomes in a multicenter cohort of RCC patients.
METHODS: Retrospective international 3 center (UC San Diego/Tokyo Medical and Dental/Emory) analysis of patients of patients with RCC with pretreatment CRP values from 2006-2017. CRP >0.5mg/dl was used as threshold for elevation and the cohort was subdivided into two groups for descriptive analysis (normal-CRP 0.5 normal and elevated-CRP>0.5). Primary outcome was overall survival (OS). Secondary outcome was recurrence-free survival (RFS CONCLUSIONS: Pre-treatment CRP was an independent predictor of recurrence free survival and overall survival in an international multicenter cohort of RCC patients. While further confirmation is requisite, our findings suggest incorporation of CRP into nomographic and risk stratification protocols. (PN) for an organ-confined >4 cm renal mass is often complex. Albeit often feasible, oncologic safety of PN in this cohort is debated. Yet, a significant portion of large renal masses that undergo radical nephrectomy (RN) prove benign or indolent. Since renal mass biopsy (RMB) is highly accurate in diagnosing oncocytic neoplasms, we assessed whether patients with a large renal mass treated by RN could have benefited from pre-operative RMB.
METHODS: We queried prospectively maintained kidney cancer databases from three institutions to identify patients who underwent RN for localized renal mass >4 cm. We excluded patients with nodal or distant metastases. Clinicopathologic variables, mass anatomic complexity and patient co-morbidities were indexed. Wilcoxon-MannWhitney test was used to compare patients with oncocytic neoplasms to the remainder of the cohort.
RESULTS: A total of 722 patients (median age 62 years, 64% male, 83% Caucasian, median serum creatinine CONCLUSIONS: Approximately 1 in 8 patients with renal mass >4 cm harbored benign or low-risk oncocytic lesions. Although these patients had larger tumors, they were younger and less comorbid than patients with oncologically higher risk lesions. As such, RMB may help calibrate the complex choice of PN vs. RN in patients with large renal mass. INTRODUCTION AND OBJECTIVES: Ureteral injuries during ureteroscopy have been reported in up to 46% of cases, including 13% involving the muscularis layer and 4% being ureteral perforations. Endoscopic injuries are commonly managed with prolonged ureteral stenting for up to 6 weeks based on historical data. We sought to Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e749
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